Integral Diagnostics Limited delivered a strong FY26 result with operating net profit after tax surging 50.1% to $47.4 million, significantly outpacing underlying revenue growth of 25.6% to $788.7 million. This substantial earnings leverage reflects disciplined operational execution and the full-year contribution of Capitol Health, which was acquired on 20 December 2024, positioning the company to deliver materially higher returns to shareholders this cycle.
Operating EBITDA expanded 30.3% to $164.8 million, with margins lifting 80 basis points to 20.9% as predicted. This represents a meaningful operational achievement, particularly given the complexity of integrating a substantial acquisition whilst scaling the underlying diagnostic services platform. The company’s ability to drive margin expansion through a period of significant corporate activity signals confidence in its operational leverage model and the synergy potential embedded within the Capitol Health combination.
Cash generation remained robust with operating free cash flow climbing 30.7% to $106.4 million, though the conversion ratio moderated from 86.5% to 82.0% year-on-year, a typically expected outcome following acquisition. More significantly, net debt fell to $298.9 million with leverage tightening to 2.3x EBITDA from 2.6x, demonstrating the company’s ability to de-lever rapidly despite deploying capital for the Capitol Health purchase. This financial discipline provides meaningful flexibility for future capital allocation decisions.
The fully franked final dividend increased 50% to 6.0 cents per share, bringing the total FY26 distribution to 9.3 cents per share. This substantial increase reflects management’s confidence in underlying earnings sustainability and the cash generation profile of the combined business, signalling conviction that the enhanced earnings power is durable rather than transient.
Investors should monitor the trajectory of like-for-like organic growth in the underlying IDX business as the Capitol integration progresses, together with management’s ability to sustain the 20.9% EBITDA margin profile or expand further. The company’s guidance has proven reliable, and whether management maintains its disciplined approach to capital deployment and continues deleveraging the balance sheet will be key indicators of capital allocation discipline ahead.
This announcement is classified as price sensitive and has been flagged as material by ASX.
View the full ASX announcement (PDF)
About Integral Diagnostics Limited (ASX: IDX)
Integral Diagnostics Limited is a healthcare services company providing diagnostic imaging services including magnetic resonance imaging, positron emission tomography, computed tomography, mammography, interventional radiology, ultrasound, and radiography. The company serves general practitioners, medical specialists, and allied health professionals across Australia and New Zealand. Founded in 1967, it operates from Melbourne, Australia.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
